Howell S B, Zimm S, Markman M, Abramson I S, Cleary S, Lucas W E, Weiss R J
Department of Medicine, University of California, San Diego, La Jolla 92093.
J Clin Oncol. 1987 Oct;5(10):1607-12. doi: 10.1200/JCO.1987.5.10.1607.
Ninety ovarian carcinoma patients failing primary intravenous (IV) combination chemotherapy were treated with cisplatin-based combination intraperitoneal therapy. Sixty-five patients had residual disease greater than 2 cm at the start of intraperitoneal therapy. Their median survival was 8 months. Twenty-five patients had disease less than 2 cm; their median survival was greater than 49 months, and the survival curve has an apparent plateau at 69%, with no relapses having occurred after 32 months. The median survival for all 90 patients was 15 months. The median duration of follow-up for all patients was 37 months. These results confirm the critical role of tumor bulk in determining the effectiveness of intraperitoneal therapy, and suggest a role for intraperitoneal salvage treatment in patients with small-volume disease.
90例初次静脉联合化疗失败的卵巢癌患者接受了以顺铂为基础的联合腹腔内治疗。65例患者在腹腔内治疗开始时残留病灶大于2cm。他们的中位生存期为8个月。25例患者的病灶小于2cm；他们的中位生存期大于49个月，生存曲线在69%处有明显的平台期，32个月后未发生复发。所有90例患者的中位生存期为15个月。所有患者的中位随访时间为37个月。这些结果证实了肿瘤体积在决定腹腔内治疗有效性方面的关键作用，并提示腹腔内挽救性治疗在小体积病灶患者中的作用。
